International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025
November 9-12, 2025 | Glasgow, Scotland, United Kingdom
The material below is provided for educational purposes only. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Health-related quality of life for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan
Healthcare resource utilization for patients with transthyretin amyloid cardiomyopathy: A real-world study in Europe, Canada and Japan
